Objective: Antiglutamate decarboxylase (anti-GAD) antibodies are associated with several neurological manifestations, like epilepsy and movement disorders. However, in daily neurological practice, it remains hard to define when to test for anti-GAD antibodies in patients with neurologic and/or psychiatric symptoms. Therefore, here, we report the patient characteristics of a large retrospective cohort of patients tested for anti-GAD antibodies in clinical practice and compare the characteristics of anti-GAD positive and anti-GAD negative patients. Methods: We blindly assessed relevant clinical symptoms and comorbidities and functional outcome with the modified Rankin Scale (mRS) in a retrospective observational cohort of all patients in which the decision to assess anti-GAD levels had been made based solely on the presence of possible associated neurological and/or psychiatric symptoms (N = 119). Results: Out of 119 patients, 17 (14.3%) were anti-GAD positive. The anti-GAD positive patients had a median age of 30 years (range: 3-64; 2 children). They all had epilepsy, with 8 (47%) patients reporting cognitive complaints. Psychiatric symptoms were less prevalent in anti-GAD positive patients, only 1 anti-GAD positive patient (6%) versus 34 anti-GAD negative patients (33%) reported psychiatric symptoms (p = 0.021). The most frequent comorbidity of anti-GAD positive patients was diabetes mellitus type 1 (n = 8). Twelve (71%) and 13 (78%) of the anti-GAD positive patients were functionally independent at the time of diagnosis and after one year, respectively (mRS score: 0 to 2). There was no significant difference in functional status at any time during follow-up compared with the anti-GAD negative group. Conclusion: Antiglutamate decarboxylase (anti-GAD) antibodies relate to epilepsy with or without cognitive complaints. However, psychiatric symptoms were almost absent in anti-GAD positive patients, and the presence of anti-GAD antibodies contributed little to the prognosis in our cohort.
Introduction
Glutamate decarboxylase (GAD) is an intracellular enzyme that catalyzes the conversion of the excitatory neurotransmitter glutamate to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Antibodies targeted at GAD may impair functioning of GABA-ergic neurons [1] . These antibodies have been found in patients with stiff person syndrome (SPS), limbic encephalitis, epilepsy, and cerebellar ataxia [2, 3] . The presence of these antibodies may coincide with comorbid autoimmune disorders, especially diabetes mellitus type 1 (DM1), which can be explained by the presence of GAD in pancreatic beta cells [4] , though anti-GAD antibodies are usually more than 100-fold higher in patients with neuropsychiatric disorders than in patients with DM1 alone [4] .
Despite increasing knowledge on anti-GAD antibodies and their possible clinical importance, uncertainty remains whether anti-GAD antibodies are involved in specific brain diseases or are merely a bystander. It remains hard to define when to measure anti-GAD antibodies. Therefore, we present a large retrospective cohort of neurological patients, suspected of autoimmune encephalitis and other neurologic diseases, in which we have performed anti-GAD analyses and compared the anti-GAD positive and negative patients aiming to define differences in patient characteristics to find clinical clues to test for anti-GAD antibodies.
Materials and methods

Study design and population
We conducted a retrospective chart review using electronic medical records of the Maastricht University Medical Centre (MUMC +) and Kempenhaeghe Epilepsy Centre (Kempenhaeghe). We included all patients between 2010 and 2014 for whom anti-GAD antibody test in serum was requested by a neurologist because of a (suspected) disease of the brain. We excluded patients when the anti-GAD analysis was performed solely in the context of DM1 or when the indication for the test could not be retrieved from clinical records.
Clinical record assessment
Demographic and clinical data including age, sex, clinical indication for the anti-GAD test, comorbidity of tumors, and history of autoimmune disorders or cancer were retrieved from the electronic patient files. Presenting symptoms as epilepsy, cognitive complaints (attention or memory deficits), psychiatric symptoms (anxiety, depression, psychosis), encephalopathy (altered consciousness, confusion), movement disorder, ataxia, or paresis, as reported by the patient and/or documented by the treating physician, were obtained from the clinical records and were retrospectively scored by a neurologist (RPWR and MCGV) or child neurologist (Suzanne Koudijs). No formal testing or psychiatric consults were involved.
We assessed functional neurological outcome using the modified Rankin Scale (mRS) [5] scored by two independent neurologists (RPWR and MCGV) at the time of anti-GAD analysis. By retrieving the clinical follow-up from the treating physician in the electronic patient files, an assessment was made regarding the mRS 1 month, 6 months, and 1 year after the analysis, to the best possible effort. After the first 29 patients, an interim analysis was made to assess intraobserver variability of the functional score. Interobserver agreement for the evaluation of functional independence (mRS 0-2 versus 3-6) was found to be high (Cohen's kappa for 29 consecutive patients: 0.854 at time of anti-GAD assessment, after 1 month: 0.915, after 6 months: 0.894, and after 1 year: 0.886). As such, further scores were assessed by one neurologist only (RPWR).
Laboratory analysis
Detection of anti-GAD antibodies was performed in routine clinical practice. For this purpose, the samples were sent to several different (inter)national reference laboratories, all accredited according to national standards. Although the assays used were expressed in U/mL, analysis of these quantitative results is hampered by the limited assay standardization in autoimmune diagnostics. Therefore, only qualitative results, i.e., negative or positive, are used in our study.
Statistical analyses
Differences in patient characteristics and clinical or diagnostic features were explored using Pearson's chi-square test (χ 2 ) for categorical data and a Mann-Whitney U test for non-normally distributed continuous variables. Interobserver variability for the evaluation of level of functioning (mRS score) [5] was calculated using Cohen's kappa. A p b 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL).
Ethical considerations
The medical ethical committees of the two participating centers, MUMC+ and Kempenhaeghe, approved the study (METC 15-4-002).
Results
Patients
Clinical data from 248 patients with a known anti-GAD antibody test between 2010 and 2014 were obtained. One hundred seventeen patients were screened solely in the context of DM1, and in 12 cases, the indication for testing could not be retrieved. This leaves 119 patients with neurological symptoms at the time of the test. All patients visited a neurologist and were clinically suspected of having an anti-GAD positive status. Seventeen (14.3%) patients were anti-GAD positive. The median age of anti-GAD positive patients was 30 years (range: 3-64 years; two children). In the MUMC+, in a secondary and tertiary care setting, there was a significantly higher proportion of patients positive for anti-GAD compared with Kempenhaeghe (25% versus 10%, p = 0.028). There were no other significant differences in patient demographics.
Indication for antibody testing in anti-GAD positive patients was suspected autoimmune encephalitis for nine (53%) subjects and refractory epilepsy for six (35%). Two (12%) patients were screened for other reasons. This did not significantly differ compared with the anti-GAD negative group.
Clinical and diagnostic features
Clinical symptoms are presented in Table 1 . All 17 anti-GAD positive patients had epilepsy, whereas there was cognitive dysfunction in eight (47%) cases. Psychiatric symptoms were significantly less common in anti-GAD positive patients than in anti-GAD negative patients (6% versus 33%, p = 0.021).
Autoimmune comorbidities were present in ten (59%) anti-GAD positive patients as opposed to nine (9%) anti-GAD negative patients (p b 0.001). Diabetes mellitus type 1 was the most common autoimmune disorder and more frequently present in anti-GAD positive patients (47% versus 1% in anti-GAD negative patients, p b 0.001). The prevalence of tumors was low in both patient groups.
Other antibodies were detected in seven patients. In the anti-GAD negative group, three patients had anti-VGKC antibodies, one had anti-NMDA antibodies, one had CASPR2 antibodies, and one had the paraneoplastic anti-Hu antibodies. In the anti-GAD positive group, one patient had concomitant GABA-receptor antibodies.
Follow-up of functional status
Functional neurological outcome scores are displayed in Fig. 1 . At the time of diagnosis, 12 (71%) anti-GAD positive patients were functionally independent (mRS score 0 to 2). Although the proportion of functionally independent patients in the anti-GAD negative group was consistently lower over time (52%), there was no significant difference at any time during follow-up.
Ten patients of the anti-GAD positive group were treated with immunotherapy at the discretion of the treating physician. All ten were treated with steroids, six in combination with immunoglobulin and 5 with plasmapheresis. Four patients received mycophenolic acid afterwards, and one patient received cyclophosphamide. We tentatively compared patients who were treated with those who were not, but there were no significant differences in functional outcomes.
Discussion
We retrospectively analyzed all patients who were tested for anti-GAD antibodies between 2010 and 2014 in our clinical centers for a neurological and/or psychiatric reason. In the patients who were anti-GAD positive, we found that psychiatric symptoms were less prevalent, and DM1 was more prevalent than in negative patients. All of our anti-GAD positive patients had epilepsy, and cognitive dysfunction was fairly common. Interestingly, anti-GAD positive patients did not have a worse functional outcome over time than anti-GAD negative patients.
Previous studies relate high anti-GAD antibody levels to SPS, limbic (or autoimmune) encephalitis, epilepsy, and cerebellar ataxia [2, 3] . However, most of these studies included a clinically homogeneous patient population, in which the clinical symptoms served as a selection criterion for the study. In contrast, we included all patients in whom the treating physician found that anti-GAD testing was relevant for clinical follow-up and possible treatment. This led to a cohort of patients with suspected limbic encephalitis or refractory epilepsy and other syndromes/symptoms and signs. We found 17 (14.3%) anti-GAD antibody positive patients, which is relatively high compared with the previously reported lower prevalence of 0 to 6% in unselected patients with epilepsy [6] [7] [8] . In addition, a recent study by Dubey et al. also shows a relatively high prevalence (20.4%) of anti-GAD antibodies in people with epilepsy with unknown origin [9] . There is a known association between DM1 and idiopathic epilepsy [10, 11] . Our study confirms this relation, as 8 (47%) patients with anti-GAD antibodies and epilepsy have a known history of DM1.
Lately, there has been interest in patients with psychosis who may have serum antibodies to neuronal antigens [12] [13] [14] . Furthermore, a recent meta-analysis suggests that anti-GAD antibodies are more common in patients with psychosis than in controls [15] . Interestingly, our study showed the contrary: we found a lower prevalence of psychiatric symptoms in anti-GAD positive patients compared with anti-GAD negative patients. It is possible that the high prevalence of anti-GAD antibodies in patients with psychosis found in the meta-analysis is driven by the co-occurrence of DM1 in this group. However, in none of the cited studies DM1 prevalence data were given. Therefore, the possible role of anti-GAD antibodies in patients with psychosis remains to be determined.
In our cohort, a history of DM1 was strongly related to positive anti-GAD titers. However, anti-GAD levels are usually more than 100-fold higher in patients with neuropsychiatric disorders than in patients with DM1 alone [4] . Unfortunately, because of the limits of standardization of autoimmune diagnostics, we were unable to compare quantitative results in our patients and to relate the autoantibody level to the clinical symptoms and comorbidities.
Though it is hard to define when to test for anti-GAD antibodies, 14.3% of patients in our population were positive. This is a relatively high percentage for autoimmune tests. In our population, the prevalence of anti-GAD positivity was even higher in the MUMC+ compared with Kempenhaeghe. The difference might be due to different populations: in Kempenhaeghe, only patients with epilepsy were seen, and all patients with refractory epilepsy may qualify for anti-GAD testing. This was compared with the MUMC+, where the anti-GAD antibody test indication apart from refractory epilepsy may also be in the context of a clinical suspicion of anti-GAD encephalitis or specific clinical syndromes like SPS or an unexplained cerebellar ataxia.
Previously, others suggested that anti-GAD-associated diseases appear to have an unfavorable response to immunotherapy and disease course over time compared with other types of autoimmune mediated encephalitis [3, 16] . This might be due to the nature of the antigen, which is an intracellular molecule [17] , or it may be due to the fact that anti-GAD reactivity occurs as an epiphenomenon and marker of an autoimmune response with different, unknown, autoimmune mechanisms [18, 19] . In our cohort, however, we could not demonstrate that anti-GAD positive patients did worse over time than anti-GAD negative patients. There was no significant difference in functional outcome between the anti-GAD positive patients treated with immunotherapy and the anti-GAD positive patients who were not treated. This might further strengthen the idea that such anti-GAD antibodies are not relevant for clinical practice but are a mere indicator of an autoimmune response.
Our study has some limitations. First, we included only retrospectively from standard clinical practice, without screening all possible patients. In this way, possibly positive patients may have been missed. Second, in contrast, the prevalence of antibodies might still be higher in our population since both centers are (at least partly) tertiary referral centers, an effect already demonstrated in studies on other autoimmune antibodies [18] . Third, during the time of testing, the phenomenon of antigen excess was insufficiently recognized for anti-GAD antibodies. This phenomenon, also known as the prozone effect, reveals a false negative result in serum with high concentrations but turns positive after the sample is diluted. This may lead to underdiagnoses of anti-GAD positive patients [19] . Finally, additional antibody testing and longitudinal follow-up of antibodies were not performed. Despite these limitations, our study remains strong in the detailed description of the unselected patient cohort which entered the anti-GAD antibody analyses, and our results directly reflect the demographics of the patients tested in clinical practice.
In conclusion, we found that in patients with neurological symptoms, an anti-GAD positive antibody status relates to the presence of epilepsy, cognitive dysfunction, and DM1 and the absence of psychiatric symptoms. From a clinical point of view, anti-GAD testing should be considered especially in patients with epilepsy of unknown origin with comorbidity of DM1 as well as cognitive complaints. Our study does not support extensive consideration in patients with psychiatric problems.
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